Get started
Author

Alessandro Pancrazzi

Observed names: A PANCRAZZI, A Pancrazzi, A. Pancrazi, A. Pancrazzi, Alessandro PANCRAZZI, Alessandro Pancrazi, Alessandro Pancrazzi (13566727), PANCRAZZI A, PANCRAZZI, ALESSANDRO, Pancrazi, Alessandro
Observed institutions: University of Siena, Mount Sinai Hospital, University of Padua, King's College London, Istituto Superiore di Sanità, University of Chieti-Pescara, University of Illinois Chicago, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Azienda Usl 8 Arezzo, Azienda Ospedaliero-Universitaria Careggi, Tumour Institute of Tuscany, Azienda Ospedaliera Universitaria Senese, Stanford Medicine, Ospedale San Donato, University of Florence, Stanford University
ORCID: 0000-0002-6943-6924
Observed ORCID: 0000-0002-6943-6924
OpenAlex ID: A5069419008
Mapping the human genetic architecture of COVID-19
2021 · COVID-19 Host Genetics Initiative, COVID-19 Host Genetics InitiativeLeadership, et al. · Nature · 983
Mutations and prognosis in primary myelofibrosis
2013 · A M Vannucchi, T L Lasho, et al. · Leukemia · 771
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
2013 · Giada Rotunno, Carmela Mannarelli, et al. · Blood · 416
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
2007 · A M Vannucchi, E Antonioli, et al. · Leukemia · 370
Whole-genome sequencing reveals host factors underlying critical COVID-19
2022 · Athanasios Kousathanas, Erola Pairo-Castineira, et al. · Nature · 327
PDF
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
2016 · Ayalew Tefferi, Terra L. Lasho, et al. · Blood Advances · 313
PDF
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
2014 · P Guglielmelli, T L Lasho, et al. · Leukemia · 310
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
2014 · A Tefferi, P Guglielmelli, et al. · Leukemia · 277
PDF
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
2005 · E Antonioli, P Guglielmelli, et al. · Leukemia · 229
PDF
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
2008 · Alessandro M. Vannucchi, Elisabetta Antonioli, et al. · Blood · 222
PDF
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
2009 · Paola Guglielmelli, Giovanni Barosi, et al. · Blood · 215
PDF
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
2010 · T. Barbui, A. Carobbio, et al. · Haematologica · 201
PDF
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
2017 · Paola Guglielmelli, Annalisa Pacilli, et al. · Blood · 187
PDF
A first update on mapping the human genetic architecture of COVID-19
2022 · COVID-19 Host Genetics Initiative, COVID-19 Host Genetics Initiative, et al. · Nature · 181
PDF
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
2007 · E. Antonioli, P. Guglielmelli, et al. · Haematologica · 163
PDF
Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation
2007 · Paola Guglielmelli, Alessandro Pancrazzi, et al. · British Journal of Haematology · 151
PDF
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
2011 · Paola Guglielmelli, Giovanni Barosi, et al. · Blood · 149
PDF
Molecular Profiling of CD34+ Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1)
2006 · Paola Guglielmelli, Roberta Zini, et al. · Stem Cells · 128
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
2012 · Vittorio Rosti, Laura Villani, et al. · Blood · 117
PDF
A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-β1 in the development of myelofibrosis
2005 · Alessandro M. Vannucchi, Lucia Bianchi, et al. · Blood · 113
Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome–Negative Myeloproliferative Neoplasms
2009 · Alessandro M. Vannucchi, Giovanna Masala, et al. · Cancer Epidemiology Biomarkers & Prevention · 112
PDF
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
2013 · J V Jovanovic, A Ivey, et al. · Leukemia · 108
PDF
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
2013 · Elisa Rumi, Daniela Pietra, et al. · Blood · 96
PDF
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group
2016 · Giada Rotunno, Annalisa Pacilli, et al. · American Journal of Hematology · 95
PDF
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
2015 · P Guglielmelli, G Rotunno, et al. · Blood Cancer Journal · 88
PDF
Works count: 113
Citation count: 7,709
H-index: 39
I10-index: 58
Year
Topic
Type